142 related articles for article (PubMed ID: 12431062)
1. Probing opioid receptor interactions with azacycloalkane amino acids. Synthesis of a potent and selective ORL1 antagonist.
Halab L; Becker JA; Darula Z; Tourwé D; Kieffer BL; Simonin F; Lubell WD
J Med Chem; 2002 Nov; 45(24):5353-7. PubMed ID: 12431062
[TBL] [Abstract][Full Text] [Related]
2. Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library.
Becker JA; Wallace A; Garzon A; Ingallinella P; Bianchi E; Cortese R; Simonin F; Kieffer BL; Pessi A
J Biol Chem; 1999 Sep; 274(39):27513-22. PubMed ID: 10488086
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity study of the ORL1 antagonist Ac-Arg-D-Cha-Qaa-D-Arg-D-p-ClPhe-NH2.
Van Cauwenberghe S; Simonin F; Cluzeau J; Becker JA; Lubell WD; Tourwé D
J Med Chem; 2004 Mar; 47(7):1864-7. PubMed ID: 15027881
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of aminoalkylazetidines as ORL1 receptor ligands.
Wu WL; Caplen MA; Domalski MS; Zhang H; Fawzi A; Burnett DA
Bioorg Med Chem Lett; 2002 Nov; 12(21):3157-60. PubMed ID: 12372523
[TBL] [Abstract][Full Text] [Related]
5. Nociceptin activation of the human ORL1 receptor expressed in Chinese hamster ovary cells: functional homology with opioid receptors.
Fawzi AB; Zhang H; Weig B; Hawes B; Graziano MP
Eur J Pharmacol; 1997 Oct; 336(2-3):233-42. PubMed ID: 9384238
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
[TBL] [Abstract][Full Text] [Related]
7. N-terminal modifications leading to peptide ORL1 partial agonists and antagonists.
Judd AK; Kaushanskaya A; Tuttle DJ; Sanchez A; Khroyan T; Polgar W; Toll L
J Pept Res; 2003 Nov; 62(5):191-8. PubMed ID: 14531842
[TBL] [Abstract][Full Text] [Related]
8. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.
Bloms-Funke P; Gillen C; Schuettler AJ; Wnendt S
Peptides; 2000 Jul; 21(7):1141-6. PubMed ID: 10998549
[TBL] [Abstract][Full Text] [Related]
9. Nociceptin inhibits capsaicin-induced bronchoconstriction in isolated guinea pig lung.
Corboz MR; Rivelli MA; Egan RW; Tulshian D; Matasi J; Fawzi AB; Benbow L; Smith-Torhan A; Zhang H; Hey JA
Eur J Pharmacol; 2000 Aug; 402(1-2):171-9. PubMed ID: 10940371
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
Ambo A; Hamazaki N; Yamada Y; Nakata E; Sasaki Y
J Med Chem; 2001 Nov; 44(23):4015-8. PubMed ID: 11689089
[TBL] [Abstract][Full Text] [Related]
11. Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.
Narita M; Mizoguchi H; Oji DE; Dun NJ; Hwang BH; Nagase H; Tseng LF
Br J Pharmacol; 1999 Nov; 128(6):1300-6. PubMed ID: 10578145
[TBL] [Abstract][Full Text] [Related]
12. In vitro inhibitory effects of J-113397 on nociceptin/orphanin FQ-stimulated.
Ichikawa D; Ozaki S; Azuma T; Nambu H; Kawamoto H; Iwasawa Y; Takeshima H; Ohta H
Neuroreport; 2001 Jun; 12(8):1757-61. PubMed ID: 11409754
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization and functional expression of opioid receptor-like1 receptor.
Wu YL; Pu L; Ling K; Zhao J; Cheng ZJ; Ma L; Pei G
Cell Res; 1997 Jun; 7(1):69-77. PubMed ID: 9261564
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.
Huang P; Kehner GB; Cowan A; Liu-Chen LY
J Pharmacol Exp Ther; 2001 May; 297(2):688-95. PubMed ID: 11303059
[TBL] [Abstract][Full Text] [Related]
15. Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.
McDonald J; Barnes TA; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Eur J Pharmacol; 2002 May; 443(1-3):7-12. PubMed ID: 12044785
[TBL] [Abstract][Full Text] [Related]
16. Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors.
Neal CR; Owens CE; Taylor LP; Hoversten MT; Akil H; Watson SJ
J Chem Neuroanat; 2003 Jul; 25(4):233-47. PubMed ID: 12842269
[TBL] [Abstract][Full Text] [Related]
17. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.
McDonald J; Calo G; Guerrini R; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):183-7. PubMed ID: 12595960
[TBL] [Abstract][Full Text] [Related]
18. Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist.
Li J; Isozaki K; Okada K; Matsushima A; Nose T; Costa T; Shimohigashi Y
Bioorg Med Chem; 2008 Mar; 16(5):2635-44. PubMed ID: 18068993
[TBL] [Abstract][Full Text] [Related]
19. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.
Zaveri N; Polgar WE; Olsen CM; Kelson AB; Grundt P; Lewis JW; Toll L
Eur J Pharmacol; 2001 Sep; 428(1):29-36. PubMed ID: 11779034
[TBL] [Abstract][Full Text] [Related]
20. Identification of a hexapeptide binding region in the nociceptin (ORL1) receptor by photo-affinity labelling with Ac-Arg-Bpa-Tyr-Arg-Trp-Arg-NH2.
Bes B; Meunier JC
Biochem Biophys Res Commun; 2003 Oct; 310(3):992-1001. PubMed ID: 14550303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
